Stories
Top Analysts Recommend Dr Reddy's, Mankind Pharma; Advise Selling HCLTech Today
- •Sundar Kewat of Ashika Institutional Equity recommends buying Mankind Pharma (target – ₹2,640, stop-loss – ₹2,418) and Dr Reddy's Laboratories (target – ₹1,300, stop-loss – ₹1,220).
- •Jay Thakkar of ICICI Securities suggests buying Dr Reddy's Laboratories (target – ₹1,300-₹1,350, stop-loss – ₹1,200) and Mankind Pharma (target – ₹2,600-₹2,650, stop-loss – ₹2,480).
- •Ajit Mishra of Religare Broking advises buying Dr Reddy's Laboratories (target – ₹1,335, stop-loss – ₹1,195).
- •Mishra also recommends selling HCL Technologies with a target range of ₹1,170-₹1,160 and a stop-loss at ₹1,260.
- •These recommendations are for short-term trading opportunities, with experts providing specific target prices and stop-loss levels.
Key Questions Answered
Analysts have shared multiple buy recommendations for Dr Reddy's Laboratories. Sundar Kewat recommends a buy with a stop-loss of ₹1,220 and a target price of ₹1,300. Jay Thakkar suggests buying with a stop-loss of ₹1,200 and a target range of ₹1,300–₹1,350, while Ajit Mishra recommends a buy with a stop-loss at ₹1,195 and a target price of ₹1,335.
Sundar Kewat recommends buying Mankind Pharma with a stop-loss of ₹2,418 and a target price of ₹2,640. Additionally, Jay Thakkar advises buying the stock with a stop-loss of ₹2,480 and a target range of ₹2,600–₹2,650, noting that its shares have gained over 2% during the past year.
Ajit Mishra from Religare Broking has recommended a sell call for HCL Technologies with a stop-loss set at ₹1,260 and a target range of ₹1,170 to ₹1,160. The stock was trading at ₹1,231.20 and had declined by more than 11% over the preceding year.
